Brusatol [CAS 14907-98-3]

Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent[1]. Brusatol increases cellular apoptosis[2].

[14907-98-3]

C26H32O11

520.53

CC([C@](C[C@@](O1)2[H])3[H])=C(O)C(C[C@]3(C)[C@]4([H])[C@]2(CO[C@@]5([C@@H](O)[C@@H]4O)C(OC)=O)[C@@]5([H])[C@@H](OC(/C=C(C)/C)=O)C1=O)=O

Apoptosis; Keap1-Nrf2

10mM

99.89

DMSO : 25 mg/mL (ultrasonic)

4°C (Powder, protect from light, stored under nitrogen)

Room Temperature

H302, H315, H319, H335

H302, H315, H319, H335